Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression.

Department of Urology, University of Michigan, 3875 Taubman Center Box 0330, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330, USA.
American Journal Of Pathology (Impact Factor: 4.6). 03/2010; 176(3):1462-8. DOI: 10.2353/ajpath.2010.090875
Source: PubMed

ABSTRACT Prostaglandin E2, which is known to contribute to cancer progression, is inactivated by the catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase (PGDH), which has tumor-suppressor activity in lung, colon, breast, and gastric cancers. Therefore, we evaluated the expression of PGDH in human bladder cancer tissue specimens and cell lines. Immunoperoxidase staining of bladder cancer tissues demonstrated that (1) PGDH is highly expressed by normal urothelial cells but (2) reduced in many low stage (Ta/Tis) bladder cancers, and (3) PGDH is completely lost in most invasive bladder cancers. Of eight cancer cell lines tested, only two relatively well-differentiated bladder cancer cell lines, RT4 and UM-UC9, expressed PGDH. Moreover, inhibition of PGDH expression in well-differentiated RT4 cells using small inhibitory RNA or short hairpin RNA resulted in a more aggressive phenotype with increased motility and anchorage-independent growth. Additionally, PGDH knockdown affected prostaglandin E2 signaling as measured by cAMP generation. These data indicate that loss of PGDH expression contributes to a more malignant bladder cancer phenotype and may be necessary for bladder cancer development and/or progression.

Download full-text


Available from: Monica Liebert, Jun 20, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRs) are a group of small, non-coding RNAs that modulate the translation of genes by binding to specific target sites in the target mRNA. This study investigated the biological function and molecular mechanism of microRNA-21 (miR-21) in human cholangiocarcinoma. In situ hybridization analysis of human cholangiocarcinoma specimens showed increased miR-21 in cholangiocarcinoma tissue compared to the non-cancerous biliary epithelium. Lentiviral transduction of miR-21 enhanced human cholangiocarcinoma cell growth and clonogenic efficiency in vitro, whereas inhibition of miR-21 decreased these parameters. Over-expression of miR-21 also promoted cholangiocarcinoma growth using an in vivo xenograft model system. The NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH/HPGD), a key enzyme that converts the pro-tumorigenic prostaglandin E2 (PGE2) to its biologically inactive metabolite, was identified as a direct target of miR-21 in cholangiocarcinoma cells. In parallel, cyclooxygenase-2 (COX2) over-expression and PGE2 treatment increased miR-21 levels and enhanced miR-21 promoter activity in human cholangiocarcinoma cells. Implications: Cholangiocarcinogenesis and tumor progression is regulated by a novel interplay between COX-2/PGE2 and miR-21 signaling which converges at 15-PGDH.
    Molecular Cancer Research 04/2014; 12(6). DOI:10.1158/1541-7786.MCR-13-0419 · 4.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The pulmonary artery endothelial cells dysfunction and injury play a critical role in chronic hypoxia-induced hypertensive process. The influence of hypoxia on the endothelial cells proliferation remains to be explored in detail. In the present study, we performed immunohistochemistry and western blot analysis and observed that hypoxia increased the expression of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in pulmonary vessels which was majorly localized in the vascular intima. Since 15-PGDH is responsible for catalyzing the 15(S)-hydroxyl group of 15-hydroxyeicosatetraenoic acid to 15-keto-6Z, 8Z, 11Z, 13E-eicosatetraenoic acid (15-KETE), the role of 15-PGDH/15-KETE pathway in the processes of hypoxia-induced endothelium proliferation and migration were detected by bromodeoxyuridine incorporation, cell cycle analysis, scratch-wound and tube formation assay. We found that 15-KETE increased cells DNA sythesis and enhanced the cell-cycle transition from the G0 /G1 phase to the S phase in hypoxia. 15-PGDH inhibitor and 15-PGDH RNA interference reversed all the alterations. Meanwhile, our results indicated that ERK1/2 signaling system was activated by 15-KETE. Additionally, 15-KETE-induced cell migration and tube formation could be reversed after blocking ERK1/2 but not p38 MAPK pathway. These observations suggest that 15-PGDH/15-KETE mediates hypoxia-induced endothelium proliferation and migration via the ERK1/2 signaling, an important underlying mechanism contributing to hypoxic pulmonary vascular remodeling.
    British Journal of Pharmacology 01/2014; DOI:10.1111/bph.12594 · 4.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cyclooxygenase-2 (COX-2), a rate-limiting enzyme in arachidonic acid cascade, plays a key role in the biosynthesis of prostaglandin E(2) (PGE(2)) upon inflammatory insults. Overproduction of PGE(2) stimulates proliferation of various cancer cells, confers resistance to apoptosis of cancerous or transformed cells, and accelerates metastasis and angiogenesis. Excess PGE(2) undergoes metabolic inactivation which is catalyzed by NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH). In this context, 15-PGDH has been speculated as a physiological antagonist of COX-2 and a tumor suppressor. Thus, overexpression of 15-PGDH has been known to protect against experimentally induced carcinogenesis and renders the cancerous or transformed cells susceptible to apoptosis by counteracting oncogenic action of PGE(2). In contrast, silence of 15-PGDH is observed in some cancer cells, which is associated with epigenetic modification, such as DNA methylation and histone deacetylation, in the promoter region of 15-PGDH. A variety of compounds capable of inducing the expression of 15-PGDH have been reported, which include the histone deacetylase inhibitors, nonsteroidal anti-inflammatory drugs, and peroxisome proliferator-activated receptor-gamma agonists. Therefore, 15-PGDH may be considered as a novel molecular target for cancer chemoprevention and therapy. This review highlights the role of 15-PGDH in carcinogenesis and its regulation.
    Biochemical pharmacology 08/2011; 82(10):1352-60. DOI:10.1016/j.bcp.2011.08.005 · 4.65 Impact Factor